Simon JA

No ORCID on file · 19 papers in corpus
rct 2025
AJOG global reports ·doi:10.1016/j.xagr.2025.100584

BACKGROUND: Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss of bone mi…

rct 2024
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

2024
F&S reports ·doi:10.1016/j.xfre.2024.06.002

ObjectiveTo investigate the efficacy of elagolix plus add-back therapy (estradiol [1 mg] and norethindrone acetate [0.5 mg] once daily) on patient-reported nonbleeding symptoms and menstrual bleeding associated with uterine fibroids (UFs) a…

review 2021
Journal of women's health (2002) ·doi:10.1089/jwh.2020.8989

Bone mineral density (BMD) changes during the life span, increasing rapidly during adolescence, plateauing in the third decade of life, and subsequently entering a phase of age-related decline. In women, menopause leads to accelerated bone …

2020
Obstetrics and gynecology ·doi:10.1097/aog.0000000000003869

ObjectiveTo investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas.Met…

nonrandomized-trial 2019
Obstetrics and gynecology ·doi:10.1097/aog.0000000000003514

OBJECTIVE: To evaluate the long-term safety and efficacy of bremelanotide as treatment for hypoactive sexual desire disorder in premenopausal women. METHODS: Women who completed the 24-week double-blind core phase of RECONNECT, composed of…

rct 2018
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002933

OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyo…

rct 2018
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exte…

2018
·doi:10.1530/ey.15.15.6

We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the c…

rct 2017
New England Journal of Medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

review 2011
Menopause (New York, N.Y.) ·doi:10.1097/gme.0b013e3182127b53

New therapies for abnormal uterine bleeding have been slow to reach the marketplace for a variety of reasons. These reasons include the availability of cost-effective therapies already available and the extraordinarily difficult and expensi…

meta-analysis 2006
Fertility and sterility ·doi:10.1016/j.fertnstert.2006.06.015

OBJECTIVE: To comprehensively review and evaluate the direct costs of endometriosis. DESIGN AND SETTING: We systematically reviewed studies published since 1990, and conducted an analysis of publicly available national databases (Healthcar…

other 2004
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2003.08.032

OBJECTIVE: The purpose of this study was to assess the in vitro effect of gonadotropin-releasing hormone agonist on natural killer cell activity in women with and without endometriosis and to ascertain whether gonadotropin-releasing hormone…

lab-animal 2001
American journal of obstetrics and gynecology ·doi:10.1067/mob.2001.110025

OBJECTIVE: A possible association of endometriosis with decreased bone mineral density in women has been proposed. It has been reported that cortical and trabecular bone mass of the distal portion of the radius is decreased in patients with…

case-report 1995
American journal of medical genetics ·doi:10.1002/ajmg.1320550423
review 1995
Obstetrics and gynecology ·doi:10.1016/0029-7844(95)00193-u

OBJECTIVE: To survey the nonsurgical diagnostic techniques for distinguishing adenomyosis, and to determine whether one technique offers diagnostic advantages. DATA SOURCES: We conducted a thorough search of the MEDLINE data base and ident…

diagnostic-accuracy 1994
Radiology ·doi:10.1148/radiology.190.3.8115630

PURPOSE: To prospectively compare conventional spin-echo magnetic resonance (MR) imaging and transvaginal sonography for the diagnosis of adenomyosis. MATERIALS AND METHODS: Twenty women with clinically suspected adenomyosis underwent MR i…

case-report 1994
Fertility and sterility ·doi:10.1016/s0015-0282(16)56776-4

The persuasive data not only illustrate a familial tendency towards adenomyosis but also emphasize that adenomyosis can be diagnosed noninvasively and accurately by MRI. A possible familial predisposition toward or a direct familial cause o…

review 1991
International journal of fertility

Intrauterine insemination is commonly performed in the treatment of infertility. Infectious complications associated with intrauterine insemination are frequently cited, though rarely reported. A review of the literature yields only five re…